Latest Bioethics Stories
- Pooled Efficacy Analyses from Phase 3 ASCEND and CAPACITY Studies Presented at 2014 American Thoracic Society Meeting - SAN DIEGO, May 20, 2014 /PRNewswire/ -- InterMune, Inc.
Advanced Disease Surveillance: Regional Lab Will Boost Global Biological Security PORT OF SPAIN, Trinidad and Tobago, May 20, 2014 /PRNewswire/ -- A new biological containment laboratory
-- Two Phase 3 trials met primary endpoint of reduction in annual rate of lung function decline RIDGEFIELD, Conn., May 18, 2014 /PRNewswire/ -- Boehringer Ingelheim announced the results of
- Investor Conference Call and Webcast Today at 8 p.m. EDT (5 p.m. PDT) - BRISBANE, Calif., May 18, 2014 /PRNewswire/ -- InterMune, Inc.
"It’s simply magnificent.
DENVER, May 1, 2014 /PRNewswire/ -- Cal-Bay International, Inc.
LEXINGTON, Massachusetts, April 30, 2014 /PRNewswire/ -- - OPUS-2, a Phase 3 placebo-controlled study of lifitegrast 5.0%; results presented at
Listen Live on Coast to Coast with George Noory as Dr.
Clinical Trials Point Toward 'ATX-101' as Potential Noninvasive Solution for Reduction of Submental Fat SAN FRANCISCO, April 26, 2014 /PRNewswire-USNewswire/ -- Skin laxity and fat buildup
PHILADELPHIA, April 24, 2014 /PRNewswire-USNewswire/ -- A new study suggests that targeting B cells, which are a type of white blood cell in the immune system, may be associated with reduced
The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...
- totally perplexed and mixed up.
More Images (1 images) »